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Abstract
Background Severe preeclampsia is associated with
increased neutrophil activation and elevated serum soluble
endoglin (sEng) and soluble Flt-1 (sFlt-1) in the maternal
circulation. To dissect the contribution of systemic
inflammation and anti-angiogenic factors in preeclampsia,
we investigated the relationships between the circulating
markers of neutrophil activation and anti-angiogenic
factors in severe preeclampsia or systemic inflammatory
state during pregnancy.
Methods and results Serum sEng, sFlt-1, placenta growth
factor, interleukin-6 (IL-6), calprotectin, and plasma a-
defensins concentrations were measured by ELISA in 88
women of similar gestational age stratified as: severe pre-
eclampsia (sPE, n = 45), maternal systemic inflammatory
response (SIR, n = 16) secondary to chorioamnionitis,
pyelonephritis or appendicitis; and normotensive controls
(CRL, n = 27). Neutrophil activation occurred in sPE and
SIR, as a-defensins and calprotectin concentrations were
two-fold higher in both groups compared to CRL
(P \ 0.05 for each). IL-6 concentrations were highest in
SIR (P \ 0.001), but were higher in sPE than in CRL
(P \ 0.01). sFlt-1 (P \ 0.001) and sEng (P \ 0.001) were
&20-fold higher in sPE compared to CRL, but were not
elevated in SIR. In women with sPE, anti-angiogenic fac-
tors were not correlated with markers of neutrophil acti-
vation (a-defensins, calprotectin) or inflammation (IL-6).
Conclusions Increased systemic inflammation in sPE and
SIR does not correlate with increased anti-angiogenic
factors, which were specifically elevated in sPE indicating
that excessive systemic inflammation is unlikely to be the
main contributor to severe preeclampsia.
Keywords Soluble endoglin  Soluble Flt-1  Placenta
growth factor  Preeclampsia  Neutrophil  Inflammation
Introduction
Preeclampsia is a pregnancy-specific hypertensive disorder
that affects 3–5% of all pregnant women [1]. The exact
etiology is unknown, but angiogenic imbalance and sys-
temic inflammation have emerged as leading causes for the
clinical signs of the disorder [2–4].
The angiogenic imbalance hypothesis proposed that
preeclampsia arises due to loss of vascular endothelial
growth factor (VEGF) activity as a result of rise in soluble
Flt-1 (sFlt-1) [5]. The loss of VEGF activity due to
increased soluble Flt-1 (sFlt-1) has since been demon-
strated in preeclamptic women [6–11]. In addition, pre-
eclamptic women have less TGF-b activity due to a rise in
soluble endoglin (sEng) [12, 13]. Importantly, these chan-
ges precede the maternal disorder. Circulating levels of
sFlt-1 and sEng are elevated several weeks prior to the
onset of the clinical manifestations of preeclampsia
[14, 15], while placenta growth factor (PlGF) is reduced in
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the first trimester of women who subsequently developed
the disorder [16–20]. These observations demonstrate an
angiogenic imbalance in preeclampsia.
Many studies have shown that increased systemic
inflammation occurs during normal pregnancy and that
inflammation is further enhanced in preeclampsia. During
inflammatory insults, neutrophils are the first leukocytes to
be recruited [21]. Neutrophil counts are increased in nor-
mal pregnancy, and further elevated in preeclampsia [22].
Mild neutrophil activation in the maternal circulation
occurs in response to circulating syncytiotrophoblastic
apoptotic debris that originate from the placenta [23] and
was reported to be confined to the maternal circulation in
pregnancy-induced hypertension [24]. Activated neutro-
phils degranulate, releasing numerous products in the cir-
culation. Alpha-defensins are specific to neutrophils, while
calprotectin is released by both neutrophils and macro-
phages. Both markers of neutrophil degranulation are ele-
vated in preeclampsia [22, 25, 26]. Interleukin-6 (IL-6), a
pro-inflammatory cytokine secreted by both activated leu-
kocytes and endothelial cells, is also elevated in serum and
plasma of women with severe preeclampsia [22, 27, 28].
Both the relationship between anti-angiogenic factors
and neutrophil activation and the magnitude of their
increase remains unknown. To dissect the contribution of
neutrophil activation and anti-angiogenic factors in severe
preeclampsia we investigated the relationships between the
circulating markers of neutrophil activation/inflammation
status (a-defensins, calprotectin and IL-6) and anti-angiogenic
factors (sEng and sFlt-1) in severe preeclampsia or systemic
inflammatory state during pregnancy.
Methods and materials
Patients and biological specimens
We analysed blood samples from 88 women with singleton
pregnancies recruited in the Low- and High-Risk Clinics and
Labour and Delivery Unit at Yale-New Haven Hospital
between December 2004 and March 2010. All women were
followed prospectively from enrollment until delivery.
Women with severe preeclampsia (sPE) (n = 45, gesta-
tional age (GA) median [interquartile range]: 30 [27–32]
weeks) were enrolled at the time of clinical diagnosis.
Controls (CRL) were healthy normotensive women who had
an uncomplicated pregnancy and delivered at term (CRL,
n = 27, GA: 29 [26–32] weeks). In addition, samples were
collected from a group of pregnant women presenting with
symptoms of systemic inflammatory response (SIR) syn-
drome (SIR, GA: 30 [27–32] weeks), who were admitted for
clinical work-up targeted to identify the underlying cause.
The Yale University Human Investigation Committee
approved the research protocol, and written informed con-
sent was obtained from all participants.
Gestational age was established based on last menstrual
period and/or early ultrasound evaluation (\20 weeks of
gestation) in all cases [29]. Severe preeclampsia was
defined based on the American College of Obstetricians and
Gynecologists criteria: gestational age [20 weeks, blood
pressure of 160 mm Hg systolic or higher or 110 mm Hg
diastolic or higher on 2 occasions at least 6 h apart, and/or
proteinuria of at least 5 g in a 24-h urine specimen or 3? or
greater on 2 random urine samples collected at least 4 h
apart [30]. Other elements of the diagnosis included: IUGR
(\10th percentile), persistent neurologic symptoms (head-
ache, visual changes), epigastric or right upper-quadrant
pain, pulmonary edema or cyanosis, oliguria (urinary output
\500 mL/24 h), serum creatinine [1.2 mg/dL, elevated
liver enzymes (greater than two times the normal) and
thrombocytopenia (\100,000 cells/lL) [30].
All patients with SIR presented with fever of [38C
(100.4 F) and at least one of the following conditions: maternal
leukocytosis ([15,000 cells/mm3), maternal tachycardia
([100 beats/min) or fetal tachycardia ([160 beats/min). All
SIR patients had a transabdominal amniocentesis to confirm or
exclude intra-amniotic infection. In the context of a negative
amniotic fluid analysis, a thorough imaging and microbiolog-
ical workup was conducted which included ultrasonography,
MRI, blood, urine and sputum cultures as deemed necessary in
the context of additional clinical manifestations. Final diag-
noses were as follows: intra-amniotic infection (n = 7),
pyelonephritis (n = 3), bloodstream infection (n = 3), gas-
troenteritis (n = 1), pneumonia (n = 1), appendicitis (n = 1).
Serum and plasma were collected during clinical assessment or
admission, as previously described [31]. Blood (serum and
citrated plasma) were collected by venipuncture, prior to
intravenous fluid administration. Serum tubes were allowed to
clot at room temperature for 30 min. All samples were spun at
800 g at 4C for 15 min, the supernatant aliquoted and
immediately stored at -80C until analyzed.
Immunoassays and other biochemical measurements
Serum sEng, sFlt-1 and PlGF were measured using ELISA
according to the manufacturer’s instructions (R&D Systems,
Minneapolis, MN). ELISA assays for serum IL-6 (eBio-
science, San Diego, CA) and calprotectin (Hycult Biotech-
nology, Uden, Netherlands), and plasma a-defensins [32]
(HNP1-3, Hycult Biotechnology, Uden, Netherlands) were
performed according to the manufacturer’s protocol.
Statistical analysis
Normality testing was performed using the Shapiro–Wilk
test. Comparisons between two groups were performed
334 Angiogenesis (2012) 15:333–340
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using Mann–Whitney tests or between 3 groups using
Kruskal–Wallis on ranks followed by Dunn’s tests as
appropriate. For immunoassay results, logarithmic trans-
formations were applied before statistical comparisons
were performed. Relationships between variables were
explored using Spearman’s Rank order correlations.
Comparison between strength of correlations was achieved
based on a z statistic. A probability level of \0.05 was
considered statistically significant. Exact P values for non-
parametric pairwise comparisons were obtained with SPSS
(PASW Statistics v.18, IBM Armonk, NY). Multiple
stepwise regression analysis was used to explore concurrent
relationships between inflammatory and anti-angiogenic
markers as dependent variables and demographic or clini-
cal characteristics as independent variables. Variables were
entered in the model based on P \ 0.05 and removed if
P [ 0.1. Statistical analyses were performed with Graph-
Pad Prism (v 4.0; GraphPad Software Inc, La Jolla, CA),
SigmaPlot 11.0 (Systat Software Inc, San Jose, CA) or
MedCalc (Broekstraat, Belgium) softwares.
Results
Demographic, clinical and outcome characteristics
Gestational age at sample collection was not different
among the 3 groups (Table 1). Compared to CRL, women
with SIR were more likely to be non-Caucasian. Women
with sPE had higher blood pressures and proteinuria
compared to both non-preeclamptic groups. Twelve of the
patients with sPE (29%) had IUGR (\10 percentile). There
Table 1 Demographic, clinical and outcome characteristics of the study groups
Variable sPE
n = 45
CRL
n = 27
SIR
n = 16
P value
Demographic and clinical characteristics
Age (years) 27 [20–36] 29 [23–32] 31 [21–38] 0.745
Non-Caucasian race, n [%]§ 28 [62] 10 [37] 13 [81] 0.013
Weight (kg) 82 [69–100] 74 [63–84] 83 [64–97] 0.377
Nulliparity, n [%]§ 28 [62] 11 [41] 10 [63] 0.172
Gestational age (weeks) 30 [27–32] 29 [26–32] 30 [28–33] 0.443
Systolic blood pressure (mmHg) 170 [160–180]a,b 114 [101–127] 108 [101–124] \0.001
Diastolic blood pressure (mmHg) 101 [92–110] a,b 68 [60–76] 60 [51–72] \0.001
Proteinuria—urinary dipstick 3 [2–3] a,b 0 [0–0] 0 [0–0] \0.001
24 h-protein excretion (g/24 h) 2.6 [1.3–5.3] NA NA NA
Neurological manifestations, n [%]§ 22 [49]a,b 0 [0] 0 [0] \0.001
IUGR, n [%]§ 12 [27]a,b 0 [0] 0 [0] 0.001
HELLP syndrome, n [%]§ 13 [29]a,b 0 [0] 0 [0] \0.001
Laboratory characteristics
WBC (91,000/mm3) 11.7 [8.6–14.7] 10.5 [8.3–12.5]b 13.6 [11.8–20.8]a 0.006
Hemoglobin (g/dL) 12.3 [11.2–13.2]b 12.2 [11.5–13.0]b 10.8 [10.2–12.2]a 0.013
Hematocrit (%) 36.1 [33.4–38.8]b 33.9 [33.6–37.2]b 32.7 [29.6–35.3]a 0.004
Differential count
Neutrophils (%) 75 [65–84]b 76 [67–79]b 82 [80–87]a 0.009
Lymphocytes (%) 17 [11–27]b 18 [15–23]b 9 [7.3–12]a \0.001
Monocytes (%) 6 [4–8] 5 [4–7] 6 [4–8] 0.840
ANC (91,000/mm3) 8.9 [6.2–11.9]b 7.6 [5.8–10.1]b 11.6 [10.0–16.2]a 0.002
Outcome characteristics
Delivery \34 weeks, n [%]§ 42 [93]a,b 0 [0]b 7 [44]a \0.001
Gestational age at delivery (weeks) 29 [28–32]a,b 39 [38–40]b 36 [29–39]a \0.001
Gestational age equates to the gestational time at which blood was taken and the time of delivery is given as the ‘‘gestational age at delivery’’
IUGR intrauterine growth restriction; HELLP Hemolysis, ELevated liver enzymes and Low Platelets; WBC white blood cell count; ANC absolute
neutrophil count
 Data presented as median [interquartile range] and analyzed by Kruskal–Wallis ANOVA
§ Data presented as n [%] and analyzed by Chi square test
a P \ 0.05 versus CRL; b P \ 0.05 versus SIR
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were significant differences in hematological parameters
among groups. Compared to CRL, women with SIR had
higher WBC and neutrophil counts and were significantly
lymphogenic. Among sPE women, there were wide varia-
tions in absolute neutrophil counts (ANC) ranging from
3,000 to 20,000 cells/mm3. There was a direct correlation
between ANC and 24 h-proteinuria (R = 0.508, P =
0.003). There was no relationship between ANC and blood
pressure levels or presence of IUGR or HELLP syndrome.
As expected, sPE women delivered at earlier gestational
ages compared to CRL and SIR.
Neutrophil activation and inflammation
Neutrophil activation, assessed by a-defensins and calpro-
tectin concentrations in the maternal circulation, showed
that the median plasma level of a-defensins in sPE was only
increased by 1.5-fold compared to CRL (Table 2, Fig. 1).
Women with SIR exhibited a further significant increase in
plasma a-defensins compared to both sPE and CRL groups
(Fig. 1). The median calprotectin concentration was
increased by approximately twofold in sPE compared to
CRL, reaching a similar level to that observed in SIR
(Fig. 1). Inflammation in sPE group was significantly
higher than CRL, as demonstrated by the twofold increase
serum IL-6 levels in sPE compared to the CTL group. The
SIR group exhibited significantly higher IL-6 compared to
both sPE and CRL groups (Fig. 1 and Table 2).
Angiogenic factors
Compared to CRL, the sPE group had an *20-fold
increase in the median serum sEng and sFlt-1 concentra-
tions (Fig. 2) accompanied by decreased PlGF (Table 2).
Importantly, despite the elevated inflammatory status in
SIR (Fig. 1), sFlt-1 and sEng concentrations in the SIR
group were similar to CRL (Fig. 2).
Inter and intra-process relationships
To further dissect the relationships between the two bio-
logical processes (inflammation and anti-angiogenic status)
in preeclamptic women, we performed correlation analyses
of biomarkers representative for each process (intra-process
correlations) using the whole cohort (3 groups). We then
analysed intra and ieter-process relationships within the sPE
group. Whole cohort correlations showed that inflammatory
markers a-defensins, calprotectin and IL-6 correlated
strongly with each other. This indicated that they were
indeed representing measurements of the same biological
process (Table 3A). Similarly, the placental angiogenic
factors (sEng, sFlt-1 and PlGF) also correlated with each
other, suggesting that their release in the circulation likely
occurs via related pathways (Table 3B). Significant positive
intra-process correlations between the angiogenic markers,
as well as the markers of inflammation, were also observed
within the sPE group (Table 4). However, inter-process
correlations in the sPE group revealed lack of correlation
between the markers of inflammation and an anti-angiogenic
state. The only inter-process correlation that reached
statistical significance was between calprotectin and PlGF
(inverse association, P = 0.011). A graphical representation
of these observations is shown in Fig. 3. Each case in our
cohort is plotted in the 3D space relative to its x, y and
z coordinates represented by its sFlt-1, sEng and IL-6 con-
centration, respectively. As shown, the only variation along
the y axis (depth: IL-6) is observed among patients in the SIR
group (green squares). In contrast, sPE cases (red circles)
scatter in the front plane of the graph delineated by their
variation in the x- (length: sFlt-1) and z- (height: sEng)
Table 2 Levels of inflammatory and angiogenic markers in maternal circulation
Variable sPE
n = 45
CRL
n = 27
SIR
n = 16
P value
Inflammatory markers
a-Defensins (pg/mL) 135.7 [127.8–153.7]a,b 122.9 [119.3–130.2]b 233.0 [182.3–351.3]a \0.001
Calprotectin (lg/mL) 40.7 [16.2–86.4]a 18.8 [13.0–39.4] 56.8 [16.5–65.3]a 0.010
Interleukin-6 (pg/mL) 1.1 [0.6–7.9]a,b 0.6 [0.4–1.0]b 18.6 [7.1–162.1]a \0.001
Pro and anti-angiogenic markers
sEndoglin (ng/mL) 70.1 [41.3–109.4]a,b 4.3 [3.5–6.1] 4.9 [7.3–7.0] \0.001
sFlt-1 (ng/mL) 21.5 [15.2–30.5]a,b 1.5 [1.1–1.8] 2.5 [1.5–4.1] \0.001
PlGF (pg/mL) 65.5 [33.0–101.2]a,b 432.9 [359.6–815.2] 203.0 [142.0–536.8] \0.001
sFlt-1/PlGF ratio 384.6 [180.3–641.9]a,b 3.4 [1.9–6.1] 9.2 [4.4–13.6] \0.001
 Data presented as median [interquartile range] and analyzed by Kruskal–Wallis ANOVA followed by multiple post hoc Dunn’s tests
a P \ 0.05 versus CRL
b P \ 0.05 versus SIR
336 Angiogenesis (2012) 15:333–340
123
coordinates. As expected, CRL cases (yellow triangles)
cluster together around the point of origin indicating minimal
variation in the 3 analytes.
Discussion
The study examined the contribution of systemic inflam-
mation and anti-angiogenic factors in preeclampsia by
investigating the relationships between circulating markers
of neutrophil activation/inflammation and anti-angiogenic
factors in severe preeclampsia and systemic inflammatory
status during pregnancy. The results reveal two important
findings. First, this case–control study demonstrates that
increased neutrophil activation and the release of anti-
angiogenic factors in preeclampsia occur at different
magnitudes in severe preeclampsia. Second, higher levels
of anti-angiogenic sFlt-1 and sEng are specific to severe
preeclampsia, and did not occur in women with systemic
inflammatory state during pregnancy.
The positive correlation between a-defensins and
calprotectin demonstrates that neutrophil degranulation
occurs in severe preeclampsia. These markers of neutrophil
activation were positively correlated with IL-6, indicating
that neutrophil activation is accompanied by inflammation
at the time of the clinical manifestation of the disease. The
cohort of severe preeclampsia patients exhibited signifi-
cantly elevated circulating sEng and sFlt-1. However, there
was no meaningful relationship between the increase in
sEng or sFlt-1 and neutrophil activation, as determined by
a-defensins or calprotectin and IL-6 release, in severe
preeclampsia. More importantly, patients with clinically
relevant systemic inflammatory state during pregnancy did
not exhibit elevated maternal sEng and sFlt-1 despite raised
levels of a-defensins, calprotectin and IL-6. This indicates
that the rise in these anti-angiogenic factors is specific to
preeclampsia and their release in the maternal circulation is
unlikely to be triggered by neutrophil activation.
Activation of neutrophils and their degranulation result
in the generation of reactive oxygen species and oxidative
stress. Many studies have proposed that oxidative stress
could be the main placental problem leading to pre-
eclampsia [33]. Recently, Redman and Sargent suggested
that oxidative stress could induce sFlt-1 and sEng release
via nuclear factor kappa-B (NFjB) to a similar or greater
extent as hypoxia [4]. In our study, women with pre-
eclampsia had a 20-fold increase in serum sEng and sFlt-1
and approximately a twofold increase in markers of neu-
trophil activation (a-defensins and calprotectin) and the
pro-inflammatory cytokine, IL-6. This is consistent with
the results of similar studies on sEng [15], sFlt-1 [14],
a-defensins [34], calprotectin [25, 35] and IL-6 [36]. Our
findings extend the results of previous studies by demon-
strating that neutrophil activation is not associated with
increases in sEng or sFlt-1 in severe preeclampsia. To
strengthen these findings, we included a group of pregnant
patients with systemic inflammation in the absence of
preeclampsia. This group failed to show any elevations in
circulating sEng or sFlt-1, despite heightened systemic
inflammation, indicating that the rise of anti-angiogenic
factors is specific to preeclampsia and independent of
systemic inflammation. Although, the present results
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Fig. 1 Scatterplots of the markers of neutrophil activation and the
inflammatory cytokine interleukin-6. Levels of a-defensins (a),
calprotectin (b) and interlukin-6 (IL-6) (c) in women with severe
preeclampsia (sPE, n = 45), pregnant controls (CRL, n = 27) and
women with systemic inflammatory response syndrome (SIR,
n = 16). The thick red line represents the groups’s median. Statistical
analysis: Kruskal–Wallis ANOVA followed by multiple post hoc
Dunn’s tests
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conflict with those of an earlier study, which had shown a
positive correlation between calprotectin and sEng in pre-
eclampsia [37], the previous results are likely to be the
consequence of gestational age differences among groups,
as acknowledged by the authors themselves [37]. To
eliminate this possible confounder, our patient groups were
matched for gestational age at sample collection and the
correlation between the two processes was limited to the
severe preeclampsia group.
The present study suggests that neutrophil activation is
unlikely to be directly involved in the release of maternal
anti-angiogenic factors in severe preeclampsia. This con-
clusion is supported by recent studies demonstrating that
complement activation was not associated with the release
of angiogenesis-related factors in preeclamptic women
[38, 39]. Interestingly, Girardi and co-workers showed that
complement activation induces the release of sFlt-1 from
monocytes and causes abnormal placental development
and fetal death in mice [40]. Thus, it is possible that
inflammatory mediators may have local autocrine or par-
acrine effects, which could amplify signaling pathways and
enhance the autocoid production of anti-angiogenic factors
or their actions. However, compliment activation did not
cause the classical symptoms of preeclampsia (increased
blood pressure and proteinuria) in the murine model stud-
ied by Girardi and co-workers. This suggests that a
threshold concentration of sFlt-1 in the maternal circulation
is critical to induce preeclampsia-like symptoms, and that
the amount produced by complement-mediated activated
monocytes was insufficient to elicit the classical signs of
preeclampsia. Indeed, the dose-dependent effect of sFlt-1 is
illustrated by the fact that neutralization of sFlt-1 below a
critical threshold eliminates the signs of preeclampsia in
mice [10].
A recent study showed that serial extraction of sFlt-1 from
the plasma of severe preeclamptic patients by apheresis
reduced circulating sFlt-1 and stabilized maternal blood
pressure, prolonging gestation in preeclamptic women [41].
This observation provides strong evidence of the role of anti-
angiogenic factors as the likely candidates for severe pre-
eclampsia. In contrast, the hypothesis that systemic inflam-
matory state per se causes preeclampsia is somewhat at odds
with clinical experience of corticosteroids used to accelerate
fetal lung maturation. A prospective double-blind random-
ized clinical trial of betamethasone confirmed the known
beneficial effects of this treatment on neonatal outcome, but
failed to show any beneficial effect to the preeclamptic
mother [42].
In conclusion, our study shows that there was no
meaningful relationship between neutrophil activation and
angiogenic imbalance in severe preeclampsia. Importantly,
the absence of increase anti-angiogenic factors in non-
preeclamptic pregnant patients with elevated systemic
inflammatory state indicates that it is unlikely that neu-
trophil activation play a central role in inducing the release
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angiogenic factors. Levels of
serum soluble endoglin (sEng)
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with severe preeclampsia (sPE,
n = 45), pregnant controls
(CRL, n = 27) and women with
systemic inflammatory response
syndrome (SIR, n = 16). The
thick red line represents the
groups’s median. Statistical
analysis: Kruskal–Wallis
ANOVA followed by multiple
post hoc Dunn’s tests
Table 3 Intra-process relationships among inflammatory (A) versus
angiogenic markers (B)
a-Defensins Calprotectin IL-6
A. Inflammatory markers
a-Defensins r = 1.000
Calprotectin r = 0.563 r = 1.000
P \ 0.001
IL-6 r = 0.544 r = 0.453 r = 1.000
P \ 0.001 P \ 0.001
sFlt-1 sEng PlGF
B. Angiogenic markers
sFlt-1 r = 1.000
sEng r = 0.852 r = 1.000
P \ 0.001
PlGF r = -0.692 r = -0.778 r = 1.000
P \ 0.001 P \ 0.001
Data presented as Spearman correlation coefficients and P values in
the entire cohort (n = 88). Italicized values depict non-significant
correlations (P \ 0.05). Perfect correlations are noted by the bold
values
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of sEng or sFlt-1 during pregnancy. More importantly,
since the increase in anti-angiogenic factors, above a crit-
ical threshold, is specific to preeclampsia, preeclampsia can
be defined as a disease where anti-angiogenic factors
disrupt the angiogenic balance, required for healthy preg-
nancy. In contrast, inflammation is consistently present in a
number of pregnancy complications and it is very unlikely
that it is the main or even the sole cause of preeclampsia.
Our study focused on severe preeclampsia, as these patients
have the greatest disease burden for maternal and fetal
morbidity and mortality. Additional research is needed to
determine whether these results also apply to mild pre-
eclampsia. Larger longitudinal population-based studies of
pregnant women will be needed to definitively ascertain
whether angiogenic imbalance or excessive inflammation
is the cause preeclampsia, and whether these relationships
differ according to disease severity.
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